Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
In this study, with a median follow-up of 25 months, the primary composite end point including cardiovascular death, MI, stroke, and hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group and in 399 (13.2%) in the placebo group (HR, 1.02
In England, it is about $150
Results are not instant and are maintained only while treatment and good sun protection continue
GLP-1 RAs are preferred second-line agents in patients with T2DM with established atherosclerotic cardiovascular diseases (ASCVD) in light of their demonstrated ASCVD benefit, high efficacy, low potential for hypoglycaemia and potential for weight loss
The slight difference between the Adjusted R 2 and Predicted R 2 values suggests that the model is reliable and can be confidently used for designing future experiments
US$ 25.87
US$ 24.52
US$ 22.44
US$ 22.10
US$ 26.80
US$ 24.00
